Volume | 93,358 |
|
|||||
News | (2) | ||||||
Day High | 16.22 | Low High |
|||||
Day Low | 15.89 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Innoviva Inc | INVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
16.07 | 15.89 | 16.22 | 16.15 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,016 | 93,358 | $ 16.06 | $ 1,498,976 | - | 12.22 - 16.865 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:37:10 | 1 | $ 15.89 | USD |
Innoviva Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1B | 63.23M | - | 310.46M | 179.72M | 2.84 | 5.59 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Innoviva News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 16.15 | 16.28 | 15.67 | 15.97 | 607,850 | -0.26 | -1.61% |
1 Month | 15.18 | 16.52 | 14.895 | 15.60 | 570,258 | 0.71 | 4.68% |
3 Months | 15.38 | 16.66 | 14.33 | 15.10 | 697,750 | 0.51 | 3.32% |
6 Months | 13.46 | 16.865 | 13.46 | 15.37 | 707,041 | 2.43 | 18.05% |
1 Year | 13.59 | 16.865 | 12.22 | 14.26 | 673,574 | 2.30 | 16.92% |
3 Years | 13.20 | 20.7056 | 10.64 | 14.88 | 751,584 | 2.69 | 20.38% |
5 Years | 14.45 | 20.7056 | 7.58 | 13.95 | 713,536 | 1.44 | 9.97% |
Innoviva Description
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. |